Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ONCONOVA THERAPEUTICS, INC.

(ONTX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Onconova Therapeutics, Inc. Announces Encouraging Clinical Data Supporting the Anti-Cancer Activity of Rigosertib-Nivolumab Combination in Advanced KRAS+ Non-Small Cell Lung Cancer

09/22/2021 | 08:00am EDT

Onconova Therapeutics, Inc. announced preliminary safety and efficacy data from an investigator-initiated Phase 1/2a trial of oral rigosertib plus the immune checkpoint inhibitor nivolumab in advanced KRAS mutated (KRAS+) non-small cell lung cancer (NSCLC). The data, which are being featured in a presentation at the 3rd Annual RAS Targeted Drug Development Summit, support the potential anti-cancer activity of rigosertib-nivolumab combination therapy in this indication and show that the doublet has been well tolerated to-date. Three quarters of patients enrolled in the trial have failed two or more lines of prior therapy and all have failed immune checkpoint inhibitors in various combinations. Demographics: All enrolled patients (12/12) failed at least one line of prior therapy with a PD-1 checkpoint inhibitor (includes evaluable and non-evaluable patients). 9 of 12 (75%) enrolled patients failed at least two prior lines of therapy. Response Results: 2 of 7 (29%) evaluable patients achieved a partial response (PR). PRs were observed in patients with two distinct KRAS mutations (G12C, G12V). 3 of 7 (43%) evaluable patients achieved disease control (PR or stable disease). 4 of 7 (57%) evaluable patients experienced progressive disease. Adverse Event Results: The combination of rigosertib and nivolumab has been well tolerated and the maximum tolerated dose has not been reached to-date. Treatment related adverse events were mostly mild with two grade 3 adverse events. 3 patients discontinued study drug (2 grade 2 genitourinary toxicities, 1 dose limiting grade 3 hyponatremia). No unexpected safety events or synergistic toxicities have been observed. This Phase 1/2a trial is designed to evaluate the combination of rigosertib and nivolumab in advanced KRAS+ metastatic NSCLC patients who have progressed on standard of care with anti-PD-1 monotherapy or anti-PD-1 in combination with chemotherapy. It includes a dose-escalating Phase 1 portion followed by a Phase 2a dose-expansion portion. Patients in the trial receive oral rigosertib twice daily on days 1-21, and intravenous nivolumab on days 1 and 15 of 28-day cycles. The primary endpoints of the trial are safety assessments to determine maximum tolerated dose and overall response rate. Secondary endpoints include progression free survival and overall survival.


© S&P Capital IQ 2021
All news about ONCONOVA THERAPEUTICS, INC.
09/29Onconova Therapeutics to Attend the Sachs 21st Annual Biotech in Europe Forum (BEF)
GL
09/28ONCONOVA THERAPEUTICS : Announces Closing of $21 Million Public Offering of Common Stock
AQ
09/27ONCONOVA THERAPEUTICS : Announces pricing of $21 million public offering of common stock
AQ
09/24AFTER HOURS WATCH LIST SCORECARD : Aehr, prgs, ontx
MT
09/24ONCONOVA THERAPEUTICS : Announces Pricing of $21 Million Public Offering of Common Stock (..
PU
09/24ONCONOVA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Other Events, Fi..
AQ
09/24Top Midday Decliners
MT
09/24Wall Street Tumbles Pre-Bell, Evergrande Risks Resurface
MT
09/24ONCONOVA THERAPEUTICS : Prices $21 Million Public Offering
MT
09/24ONCONOVA THERAPEUTICS : Announces proposed public offering of common stock
AQ
More news
Analyst Recommendations on ONCONOVA THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 0,23 M - -
Net income 2021 -20,4 M - -
Net Debt 2021 - - -
P/E ratio 2021 -2,97x
Yield 2021 -
Capitalization 71,9 M 71,9 M -
Capi. / Sales 2021 308x
Capi. / Sales 2022 288x
Nbr of Employees 12
Free-Float 99,5%
Chart ONCONOVA THERAPEUTICS, INC.
Duration : Period :
Onconova Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ONCONOVA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 3,46 $
Average target price 11,50 $
Spread / Average Target 232%
EPS Revisions
Managers and Directors
Steven M. Fruchtman President, Chief Executive Officer & Director
Mark P. Guerin Chief Financial Officer
James J. Marino Chairman
Matthew Parris Vice President-Clinical Operations
Mark Stephen Gelder Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
ONCONOVA THERAPEUTICS, INC.-48.33%75
CSL LIMITED4.48%100 550
WUXI BIOLOGICS (CAYMAN) INC.10.21%61 723
SAMSUNG BIOLOGICS CO.,LTD.6.54%48 773
ALEXION PHARMACEUTICALS, INC.0.00%40 336
BIOGEN INC.10.35%40 270